RxDoctor Payments Data

Timothy Sparta, PA

Physician Assistant · Millville, DENPI 1376857011

Payments from drug & device makers

$1,705in general payments, 2019–2025

Across 55 payments — averaging $31.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$397
  • AstraZeneca$313
  • AbbVie$214
  • Corcept Therapeutics$124
  • Biohaven Pharmaceutical Holding Company Ltd.$122
  • Gilead$118
  • plus $417 from 11 others

What the payments were for

  • Food & beverage$1,705100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,705 in reported general payments places this provider in the 85th percentile of 527 physician assistant providers in Delaware.

See all physician assistant providers in Delaware

Medicare billing

Part B allowed, 2024
$85,249
Medicare patients
324
Services billed
902

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$76,222
JardianceEmpagliflozin24$39,960
MounjaroTirzepatide24$33,100
EliquisApixaban18$25,039
FarxigaDapagliflozin Propanediol11$17,103
Sumatriptan Succinate21$6,416
Rosuvastatin Calcium114$2,072
Ezetimibe39$1,580
Metoprolol Succinate61$1,325
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide12$1,220
Atorvastatin Calcium145$1,128
Levothyroxine Sodium91$896
Losartan Potassium75$851
Venlafaxine Hcl ErVenlafaxine Hcl18$817
Gabapentin63$792

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$397$76,22273 claims
Lilly USA, LLCMounjaro, Olanzapine$88$33,66136 claims
PfizerEliquis$58$25,03918 claims
AstraZenecaFarxiga$313$17,10311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 527 physician assistant providers in Delaware.

Other physician assistant in Millville

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →